UPDATE: UBS Downgrades Celgene (CELG) to Neutral: Taking Some Off The Table
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
Cantor Fitzgerald Reiterates a 'Buy' on Celgene (CELG); Raising PT on Increased Confidence
September 7, 2012 10:21 AM EDTCantor Fitzgerald reiterates a 'Buy' on Celgene (NASDAQ: CELG) price target of $82.00 (from $76.00).
Analyst, Mara Goldstein, said, "We are raising our price target to $82 based on data from apremilast's psoriatic arthritis program. In addition to previously announced results of the PALACE 1 trial, two additional trials, PALACE... More
Celgene (CELG) Unit Reports Statistically Significant Data for ACR20 in Phase III
September 6, 2012 7:42 AM EDTCelgene International SÃ rl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that statistical significance for the primary endpoint of ACR20 at week 16 was achieved for patients receiving apremilast 20 mg and 30 mg BID in both the PALACE-2 & 3 phase III studies. Positive PALACE-1 data was previously reported. PALACE-2 & 3 are the second and third of three pivotal phase III, randomized, placebo-controlled studies evaluating the Companys novel, oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) in patients with psoriatic arthritis who had received or failed oral disease-modifying antirheumatic drugs (DMARDs), and/or an anti-tumor necrosis factor... More
